Johnson & Johnson stock follows raised 2026 guidance

Published on 09/25/2026 at 13:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock posted adjusted EPS of USD 2.90 in Q2 2026, above the USD 2.84 consensus. Revenue reached USD 25.31 billion, up 6.6 percent year over year.

Modern hospital operating room with robotic surgical arms positioned above a draped patient, surgeons in blue sterile gowns monitoring vital-sign and anatomy screens, bright overhead surgical lighting, stainless steel instrument trays in the foreground — Johnson und US4781601046 zeigen modernen Krankenhaus OP mit Robotik Chirurgie und medizinischen Bildschirmen, Illustration mit AI erstellt.

Johnson & Johnson (ISIN US4781601046) stood at USD 270.68 on the NYSE on September 24, 2026, after the healthcare group raised its 2026 outlook. The latest quote was USD 1.51 above the prior close of USD 269.17, while the stock remained USD 10.39 below its 52-week high of USD 281.07.

Raised guidance meets stronger demand

At the Deutsche Bank 2026 Healthcare Summit on September 17, 2026, management outlined a higher-growth path for Johnson & Johnson. According to Investing.com, the company expects 2026 free cash flow of USD 21 billion and continues to target annual sales above USD 100 billion.

The operating backdrop is strongest in Innovative Medicine. Q2 2026 sales in that segment reached USD 16.38 billion, up 7.8 percent year over year, while oncology sales increased 17.3 percent to USD 7.41 billion, according to The Globe and Mail.

Q2 earnings beat consensus

Johnson & Johnson delivered adjusted EPS of USD 2.90 in Q2 2026, exceeding the USD 2.84 consensus by USD 0.06. Revenue reached USD 25.31 billion versus the USD 25.06 billion estimate, a USD 0.25 billion beat and 6.6 percent growth from the prior-year quarter, according to MarketBeat.

The product mix also shows the tension in the portfolio. Darzalex sales rose 18.9 percent to USD 4.21 billion and Tremfya sales increased 72.5 percent to USD 2.05 billion, while Stelara sales fell 55.2 percent to USD 740 million in the same quarter.

Valuation leaves less room

MarketBeat lists a consensus Moderate Buy rating and an average target price of USD 274.13. That target is USD 3.45 above the latest USD 270.68 quote, while the 52-week range runs from USD 177.32 to USD 281.07.

Investor Day sets the next checkpoint

Johnson & Johnson's Investor Day is scheduled for December 8, 2026, according to Investing.com. That event will test whether the raised sales outlook and USD 21 billion free cash flow target are supported by fresh operating detail.

Stock holds above USD 270

Johnson & Johnson stock stood at USD 270.68 on the NYSE on September 24, 2026, with a market capitalization of USD 652.31 billion and volume of 6,155,759 shares. The quote was USD 10.39 below the 52-week high and USD 93.36 above the 52-week low.